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Abstract: During the last 10 years we have witnessed the development of a new field in research termed Stem Cell Ther-
apy. Classically, it was considered that cells had a limited division and differentiation ability; however, this dogma was 
challenged when new exciting results about cell multi/pluripotency were presented to the scientific community. It was 
found that cells from one adult tissue source were able to originate cells of a very different type. The possibility of trans-
planting these cells into damaged organs with the aim of substituting sick or dead tissue, triggered many studies to under-
stand the plasticity of the stem cells and their potential in pathological situations. Nowadays, much more is understood 
about stem cells, although of course, many questions, especially about their mechanism of action, still need to be an-
swered. Their benefit after transplantation has been shown experimentally and even clinically in some cases; however, the 
degree of stem cell contribution through their own differentiation into the transplanted tissue, has turned out to be gener-
ally low, and increasing evidence indicates that a trophic effect must play an important role in such a benefit. A better un-
derstanding of the paracrine mechanisms involved could be of great relevance in order to develop new therapies focused 
on stimulating endogenous cells. On the other hand, more sophisticated methods for cell transplantation combined with 
bio-engineering techniques have been devised in cardiac disease models. In this review we will try to provide a critical 
overview of the stem cell studies performed until now and to discuss some of the questions raised about the mechanisms 
that are involved in their putative reparative effect in cardiovascular diseases, and their origin. 
INTRODUCTION 
The presence of progenitor cells with the ability to re-
place senescent tissues in the different organs was reported 
some time ago; however, this potential was believed to be 
restricted to certain tissues, and only during the last few 
years has the existence of rare cell populations with multipo-
tent or even pluripotent capabilities been described in most 
adult tissues. Such findings have been especially striking in 
organs like the heart and the brain, which were typically con-
sidered organs with extremely low self-renewal capacity, 
consisting of cardiomyocytes (CMs) and neurons classically 
considered cells that lose their potential to proliferate right 
after birth. However, although the presence of progenitors 
with a proliferative and differentiation capacity has been 
shown, unfortunately, in the case of severe diseases like 
myocardial infarction (MI) or stroke, their potential seems 
not to be sufficient to restore a damaged organ. A deeper 
understanding of the origin and “behavior” of these stem 
cells is mandatory to be able to manipulate them and induce 
their activation and differentiation to regenerate the damaged 
tissues. 
Although the risk of death in patients with myocardial in-
farction during the acute stage has been significantly dimin-
ished, this has brought about an increased incidence of 
chronic heart problems. Drug treatments can only partially 
improve the patient’s quality of life and cannot counteract 
the adverse remodeling processes that take place after acute 
infarction. As consequence of the ischemia, a progressive 
contractile dysfunction of the viable myocardium will follow 
which will end up in many cases in heart failure [1]. Taking  
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these aspects into account, an ideal therapy should be able to 
regenerate the damaged tissue providing new cells, which 
ideally could be applied during the first stages of the diseases 
with the aim of reversing the initial damage and controlling 
the remodeling processes initiated as a consequence of the 
acute ischemia. 
In this article, we will review the potential of the differ-
ent types of stem cells identified until now, focusing on their 
in vitro capacity to differentiate to mesoderm-derived cells 
like CMs and vascular cells, and therefore, their application 
in animal models of myocardial infarction. Finally, we will 
describe and discuss some of the more relevant clinical trials 
in the field of cardiac diseases. 
STEM CELLS AND CARDIAC DISEASE 
The replacement of the dead tissue in the ischemic heart 
by new CMs (and vascular cells) has become one of the 
main objectives of stem cell therapy in cardiac disease. In 
general, it has been demonstrated that stem cells can be ma-
nipulated in vitro to differentiate into different mesodermal 
cell types, which express tissue specific markers and in some 
cases, functionally behave like them. Thus, the embryonic 
stem cells (ESCs), which are isolated from the inner cell 
mass of the embryo, are the cells with the greatest differen-
tiation potential, since it is possible to derive them to all so-
matic and germinal tissues. A number of studies performed 
with mice and human ESCs have addressed the basic signal-
ing mechanisms involved in tissue development but also the 
potential to manipulate them in vitro and in vivo for tissue 
regeneration [2]. On the basis of these studies and knowl-
edge about embryo development, the differentiation potential 
of the adult stem cells (SC) has also been broadly tested. The 
cardiac (and vascular) differentiation potential of embryonic 
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and adult stem cells and their regeneration capability in ani-
mal models of cardiac ischemia will be discussed next. 
Stem Cell-Based Experimental Studies 
Embryonic Stem Cells (Escs) 
The in vitro ESC differentiation potential towards cells 
belonging to the three germ layers is well described. ESCs 
differentiate into CMs (reviewed in [3] and [4]) by culturing 
in suspension as embryoid bodies followed by plating them a 
few days later. Although there is a high variability rate, 
spontaneous differentiation with beating areas can be gener-
ally detected [5]. Also, their co-culture with the primary vis-
ceral endoderm cell line END-2, gives a successful differen-
tiation [6]. Importantly, not only specific cardiac proteins 
expression but also electromechanical coupling and electro-
physiologic specialization can be detected [5,7,8]. Further-
more, their cardiomyogenic potential has been confirmed in 
vivo when transplanted, after in vitro differentiation, into 
ischemic hearts [9,10]. However, it seems that no specific 
directed cardiac differentiation occurs in the heart. Thus, 
when undifferentiated human ESCs are injected in the hind 
limb they give rise to the same proportion of cardiomyocytes 
as when they are injected in the heart [11]. Besides, teratoma 
formation has been detected in all cases. The high risk of 
tumor formation makes it mandatory to pre-differentiate the 
cells towards CMs and to develop techniques to isolate a 
highly purified population of CMs. Importantly, it has been 
shown that ESC-derived CMs are terminally differentiated 
cells that are functionally equivalent to CMs isolated from 
the heart (reviewed in [12]). Unlike mouse ESCs, human 
ESCs possess a certain degree of proliferation in vitro 
[13,14] and in vivo [9]. Thus, the cells can be expanded and 
differentiated in bio-reactors and genetically selected by us-
ing transgenes encoding fluorescent reporters or antibiotic-
resistance genes controlled under a cardiac-specific promoter 
[15-18]. These strategies have been shown to produce almost 
pure CMs that once transplanted into the heart do not seem 
to form tumors; however, these genetic approaches present 
many obvious restrictions to their clinical application. On the 
other hand, interesting experiments have been performed by 
the groups of Terzic [19] and Murry [20], in which ESC car-
diac specification was guided by specific cytokine treatment 
(TNF-? or Activin-A plus BMP4 combination respectively), 
and a pure cardiac population was obtained that, once trans-
planted in the infarcted heart, is able to partially regenerate 
the muscle with no tumor formation reported. Furthermore, 
these cells positively affected cardiac performance and also, 
when transplanted with a cocktail of pro-survival cytokines, 
induced a significantly greater improvement of cardiac func-
tion [20]. A caveat to these results is provided by a recent 
study published by Mummery’s group, which shows that 
transplantation of human ESC derived CMs in a mouse 
model of MI induced an improvement in cardiac function 
(together with cell engraftment); however, this effect disap-
peared at 3 months [21]. Thus, long-term studies need to be 
performed in order to determine the safety and efficacy of 
ESCs. Finally, another major issue that needs consideration 
together with the tumorigenic potential is the immune rejec-
tion provoked by the ESCs. Nuclear transfer in order to ob-
tain non-immunogeneic patient-matched ESCs, creation of 
hematopoietic cells lines derived from human ESCs or ex-
pression by the ESCs of recipient specific major-
histocompatibility complex molecules, are some approaches 
that are being studied. 
Bone Marrow-Derived Sc 
In adult tissues, stem cells with differentiation potential 
have been found, albeit with a more limited than ESCs. 
However, the in vitro differentiation potential of Bone Mar-
row (BM)-derived cells towards CMs is not yet clear. Early 
studies performed by Fukuda et al. showed differentiation of 
BM-derived stromal cells towards spontaneous contractile 
cells with cardiac phenotype when treated with 5-Azacitidine 
[22]; however, subsequent studies showed that the differenti-
ated cells also expressed skeletal myoblast markers. Moreo-
ver, other laboratories have not been able to reproduce these 
experiments. In vivo, however, although the degree of differ-
entiation still remains controversial, many reports have 
shown cardiac differentiation potential from BM-derived 
cells. This evidence was supported by human sex-
mismatched heart transplantation, where cardiac chimerism 
was determined in transplanted patients [23-26]. The per-
centage of contribution however, was very low in all these 
cases (0.02% to 0.07%) which raised questions about the 
physiological relevance of their contribution. On the other 
hand, a higher differentiation rate to endothelial cells was 
found.  
In one of the first studies performed in a murine model, 
GFP positive BM-derived hematopoietic cells were trans-
planted into a lethally irradiated mouse model of acute MI. 
As a result of the transplantation, only a very low rate of 
GFP
+
 CMs (? 0.02%) were found in the perinfarct region 
(and 3.3% of endothelial cells) and importantly, it was 
proven that such cell plasticity could be due to a fusion phe-
nomenon [27,28]. On the other hand, studies from Anversa’s 
group have shown that transplantation of the BM fraction 
Lin
-
/ckit
high
 in the infarcted myocardium, could contribute to 
nearly 50% of de novo CMs, endothelial and smooth muscle 
cells [29]. Unfortunately, these experiments have not been 
reproduced by other independent laboratories using similar 
or even the same models, leading to a general skepticism 
regarding the potential of BM cells to differentiate into func-
tional cardiomyocytes [30,31]. Some interesting studies have 
been performed with heterozygous cKit mutant mice 
Kit
W
/Kit
W-V [32]. When MI was provoked, the abnormality 
led to dilated cardiomyopathy and death from cardiac failure 
but failing hearts could be rescued by transplantation of wild 
type BM cells. Although an angiogenic positive effect of the 
cKit cells was demonstrated, no cKit-derived cardiomyo-
cytes were found. Further studies are needed in order to bet-
ter understand the role of the cKit
+
 cells in cardiac regenera-
tion. On the other hand, the existence of rare cell populations 
in the BM with much higher differentiation capability has 
recently been demonstrated. MAPCs were the first cells de-
scribed with the capability to give rise to cells derived from 
the three germinal layers [33,34]; subsequently, other cells 
like the MIAMI [35], VSEL [36], SSEA1+ [37], Oct4+ [38] 
and SSEA1+ and SSEA3+ BM-derived clonal cells [39] 
have also been described. More detailed molecular studies 
need to be performed in order to determine whether these 
putative different cell types represent the same population at 
Stem Cells and Cardiac Disease Current Stem Cell Research & Therapy, 2008, Vol. 3, No. 4    3 
different differentiation stages. It has been demonstrated that 
some of these populations possess cardiac potential, like the 
VSEL cells [40] or the ones described by the group of 
Losordo [39], which have been demonstrated to contribute in 
vivo to CMs (4.1% ±3.1% in the peri-infarct region) together 
with endothelial and smooth muscle cells (5.4%±3.3% and 
5.8%±2.9% respectively), and which induced a favorable 
remodeling and improvement in the cardiac function of the 
ischemic heart. An augmentation of proliferation and preser-
vation of the perinfarcted area at risk by up-regulation of 
paracrine factors involved in angiogenesis, apoptosis and 
proliferation, was also demonstrated. Interestingly, these 
cardiac cells were negative for the cKit marker. Also, the 
pluripotent BM-derived SC population MAPCs, was tested 
as a candidate for cardiac repair in acute and chronic infarct. 
Although cardiac differentiation was not proven due to rapid 
disappearance of the transplanted cells (probably due to the 
ischemic conditions of the tissue and immunological reaction 
against the non-host GFP or ?-galactosidase cell markers), 
improvement of the cardiac function, which was not 
achieved in the control group transplanted with BM cells, 
was demonstrated [41,42]. In the acute model, a reduction of 
the infarct size and induction of the neoangiogenesis was 
shown. In vitro analysis showed that MAPCs could have had 
a trophic effect by secretion of inflammatory (monocyte 
chemoattractant protein-1 (MCP)-1) and angio/arteriogenic 
(VEGF, platelet derived growth factor (PDGF)-BB, and 
TGF-?1) factors, together with an anti-apoptotic protective 
effect of the myocardium at risk. Importantly also, differen-
tiation towards endothelial (venous or arterial) and smooth 
muscle cells has been demonstrated in vitro and in other in 
vivo ischemia models [43,44].  
Adipose-Derived Sc (Adsc) 
The adipose tissue, like the BM, contains a population of 
cells that has extensive self-renewal capacity, its expansion 
being not only due to mature adipocyte hypertrophy but also 
to the presence of precursor cells in the stroma-vascular frac-
tion (SVF). Planat-Benard et al showed that this particular 
cell fraction was able to rescue lethally irradiated mice as 
consequence of reconstitution of the major hematopoietic 
lineages [45]. Furthermore, it was shown that the ADSCs 
could differentiate not only into hematopoietic cells but also 
into mesenchymal cell types (osteoblasts and adipocytes), 
and most importantly, into vascular endothelium [46] and 
cardiac-like cells [47]. Thus, when fresh SVF are cultured in 
methylcellulose, they become organized forming contractile 
clumps which contain cardiac cells with ventricle- and atrial-
like phenotype. Importantly, electrophysiological studies 
performed on early cultures revealed a pacemaker activity of 
the cells. Moreover, stimulation by adrenergic or cholinergic 
agonists in more mature differentiated cells was detected. 
Similarly, cultured cells could give rise to endothelial cells 
whose beneficial effect has been demonstrated in vivo by 
their contribution to neoangiogenesis in hindlimb ischemia 
mice models [48] and by their ability to secrete angiogenic 
and antiapoptotic factors [49]. On the other hand, ADSC 
cardiac differentiation has been recently demonstrated when 
transplanted in acutely infarcted mice [50], and an improve-
ment in the cardiac function has been proven after CD29+ 
SVF cell transplantation [51]. Importantly, ADSCs also in-
duced an improvement in the cardiac function associated 
with an increased vasculature in an acute/reperfusion ische-
mia model in pig [52]. More basic studies are required to 
better characterize these cell populations which, due to their 
differentiation potential and simple and innocuous isolation 
technique, appears to offer a potential clinically useful 
source of cells for therapeutic transplantation in the heart.  
Resident Cardiac Stem Cells 
The existence of cardiac progenitor cells (CPCs) in the 
adult heart was first reported by Anversa’s group [53]. Cells 
were shown to be distributed in small clusters in the intersti-
ces adjacent to the cardiomyocytes and were isolated and 
characterized by a Sca-1
-
cKit
+
 phenotype. These cells pos-
sess self-renewing, clonogenic and multipotent abilities with 
potential to differentiate towards cardiomyocytes, endothe-
lial and smooth muscle cells. Importantly, an increase of the 
CPC pool in the heart after acute myocardial infarction was 
reported [54] and an improvement in cardiac function after 
their transplantation in rat ischemic heart muscle was also 
demonstrated [53]. Recently, their ability to transverse the 
vessel barrier to engraft into the ischemic heart after intra-
coronary injection has also been shown [55]. A population of 
Sca-1
+
cKit
-
 cardiac progenitor cells which, after stimulation 
in vitro with 5-Azacytidine, express cardiac markers has also 
been described [56], although no spontaneous beating cells 
could be detected. Importantly, when these cells were intra-
venously transplanted in previously infarcted and reperfused 
mice, they could home to the injured heart and differentiate 
towards cardiomyocytes, 50% of the differentiated cells be-
ing consequence of fusion events [56]. An independent labo-
ratory in Japan was also able to isolate this Sca1
+
 population 
and to differentiate it in vitro towards cardiac cells (surpris-
ingly with oxytocin but not with 5-azacytidine) and also in 
vivo, finding Sca1+ derived endothelial and smooth muscle 
cells [57,58]. Furthermore, a Sca-1
+
cKit
LOW
 cardiac side 
population defined by the expression of the transport protein 
Abcg-2, could be differentiated towards cardiomyocytes 
upon co-culture with rat cardiomyocytes [59,60]. Other stud-
ies have shown the ability of some cells derived from the 
murine and human heart to form clusters in vitro when cul-
tured in suspension (named “cardiospheres”) [61]. These 
clusters contain clonally derived cells which organize in a 
core composed by proliferating c-kit-positive cells and a 
surrounding layer of spontaneously differentiated cells that 
express markers characteristic of cardiac, endothelial and 
mesenchymal cells. Moreover, their transplantation into im-
munosuppressed infarcted mice improved their cardiac func-
tion. Also, proliferation and differentiation of these cells has 
been reported [62]. Finally, another population of cardiac 
stem cells has been recently described in rodent and human 
embryo, newborn and adult right atrium hearts which is 
characterized by the expression of the LIM-homeodomain 
transcription factor islet-1 [63]. Their self-renewal and CM 
differentiation potential has been demonstrated; unlike the 
other cell populations, these cells do not express cKit or 
Sca1 receptors. It will be interesting to know whether such a 
population can be stimulated in the adult heart and what role 
they can play in the ischemic heart. 
Although many studies have focused on the potential of 
SC to differentiate into CMs, in order to regenerate the heart 
tissue, it is equally important to restore the vascular net, 
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which will supply the new repopulated tissue with oxygen 
and nutrients. Importantly, most of the SC previously de-
scribed (ESCs, SVF and several populations of the BM like 
the EPCs (Endothelial progenitor cells) also possess the ca-
pacity to differentiate into vascular structures.  
Skeletal Myoblasts and Satellite Cells 
Although some initial studies suggested that skeletal 
myoblasts could differentiate towards CMs, their lack of 
cardiac differentiation potential has been clearly demon-
strated. Recently, however, the existence in the skeletal mus-
cle (Sk) of a non-satellite cell population (termed SPOC 
cells) has been shown, which can differentiate to spontane-
ously beating cells with cardiac features [64]. Furthermore, 
another population, which unlike SPOC cells, is phenotypi-
cally characterized by the expression of the CD34 marker, 
has also been identified. Importantly, when the Sk-CD34+ 
cells were transplanted in the ischemic heart, they induced an 
improvement in the function [65]. It would be interesting to 
determine their putative presence in the human skeletal mus-
cle, which has not been described yet. On the other hand, 
referring to the skeletal myoblasts, despite their lack of car-
diac differentiation potential, many studies have been per-
formed in both small and large animals models of MI, show-
ing also an improvement in cardiac function after their trans-
plantation (Reviewed in [66] and [67]). These beneficial 
effects could be due, at least partially, to a cell paracrine 
effect, by secretion of factors that can induce the activation 
of the angiogenesis processes and modulation of the compo-
sition of the extracellular matrix. Besides, skeletal myoblasts 
present high resistance to hypoxia, which give them an ad-
vantage over other types of cells which, when transplanted, 
quickly disappear due to the low oxygen environment. 
Moreover, the fact that myoblasts are progenitor cells al-
ready committed to muscle differentiation with low prolif-
eration rate avoids the tumorigeneic risk that other cells may 
have. On the other hand, the main limitation of skeletal 
myoblasts is their inability to electromechanically couple 
with the surrounding CMs, which it has been argued, could 
increase the risk of arrhythmias.  
Conclusions from the In Vivo Experimental Results 
From all the extensive in vivo data published until now, 
there are some conclusions and important points that need to 
be discussed: (1) the low levels of cell engraftment that have 
been found in the vast majority of the animal experiments 
performed; (2) the low degree of cell differentiation in vivo 
and (3) the near lack of correlation between the type of cells 
transplanted and the functional effect observed. 
Cell retention and survival are one of the main technical 
limitations that stem cell therapy presents nowadays. In the 
cardiac ischemic tissue, the hypoxic environment together 
with the inflammation - a process typical of the MI acute 
stage also provoked by the needle injection during the cell 
transplantation - significantly diminish the number of en-
grafted cells which in many cases end up disappearing a few 
weeks after the transplant. However, despite their limited 
engraftment, their positive effect in the sick heart has been 
demonstrated in many studies. Initially, this benefit was at-
tributed to the differentiation potential of the stem cells to 
cardiac or vascular cell types, but it is clear now that the per-
centage of cells that truly differentiate is very low and cannot 
be fully responsible for the positive effect. Besides, several 
cell types with very different tissue-origin and differentiation 
potential have been shown to induce similar benefits. There-
fore, it has been hypothesized that a paracrine effect might 
be, at least partially, the cause of this effect. Cytokines se-
creted by the transplanted cells could promote angiogenesis, 
cell proliferation and survival, or extracellular matrix com-
position changes and might even attract/activate endothelial 
or cardiac progenitor cells present in the organism (Fig. 1). 
This hypothesis has been proven by injection of conditioned 
media recovered from cultured SC, which can also produce 
some benefit in the injected hearts [68,69]. On the other 
hand, direct treatment with single specific cytokines has also 
been tested; however, the improvement induced has been 
significantly lower than with the transplanted cells, probably 
due to the instability of the cytokine and also because the 
paracrine cell effect must be consequence of a combination 
of several factors rather than only one. On these grounds, 
several bio-engineering approaches have been proposed and 
tested in order to improve the degree of cell engraftment and 
survival. Transplantation of stem cells embedded in matrigel 
or collagen matrixes have been shown to improve the level 
of engraftment and hence, the cardiac function [70]. Syn-
thetic membranes where cells can be grown in monolayer 
and be applied as a patch, have also been found to produce 
significant benefit [71] and more sophisticated techniques, 
such as 3D scaffolds where cells can integrate, are also being 
tested [72]. Finally, several experiments have shown a 
greater positive effect when genetically modified cells ex-
pressing some anti-apoptotic factors like Akt or Bcl2 are 
transplanted [69,73]. Thus, the combination of stem cell 
therapy with other scientific fields like the bio-engineering 
and gene therapy could greatly improve the regenerative 
potential of these cells. 
Clinical Trials and Therapeutic Perspectives 
Although more basic studies are needed in order to un-
derstand “SC behavior” and also the mechanisms involved in 
cardiac repair, a number of early phase clinical as well as 
randomized trials have been performed. Based on the en-
couraging experimental results and their putative feasibility 
and safety, skeletal myoblasts and bone marrow derived SC 
(Hematopoietic SC (HSC) and Mesenchymal SC (MSC)) 
have been tested. Also, their autologous application which 
avoids the need for immune-suppression has been an impor-
tant factor in their choice. More recently, ADSCs have been 
introduced in the clinical arena.  
Clinical Trials Using Skeletal Myoblasts 
The first clinical trial with skeletal myoblasts was started 
in 2000 on a series of 10 patients with severe ischemic heart 
failure (LVEF?35%) [74,75] (See Table 1). This group 
showed an increase in the LVEF during the first year (24.3% 
± 4% to 31% ± 4.1%; p=0.001) which remained stable in 
time over 6 years of follow-up [76]. However, tachycardia 
episodes were detected in 5 of these patients, requiring the 
implantation of a defibrillator. Even with this, 3 of the pa-
tients still suffered arrhythmic storms, which aroused some 
concerns about the safety of myoblast transplantation. Re-
garding this issue, in vitro studies showed that neonatal car-
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diomyocytes that were co-cultured with skeletal myoblasts 
suffered a decrease in the conduction velocity together with 
arrhythmic contractions [77]. Interestingly, this effect was 
cell-dose dependent and was detected as long as co-cultures 
contained more than 20% of myoblasts but never when the 
percentage was lower than 5%. Also, in vivo experiments in 
rats showed the same cell-dose dependency [78]. In patients, 
although some cases of arrhythmias have been reported, 
overall, an improvement in the cardiac function together 
with an increase in the viability and perfusion has been 
found in most of the clinical trials published so far [79] [76] 
[80-85]. Some studies like that published by Gavira et al. 
have been successful with no cardiac arrhythmia reported 
after one-year follow-up [80]. In this study, cells were cul-
tured in autologous serum instead of bovine serum, which 
might be associated with lower inflammation. Echocardi-
ography results showed an increase in the ejection fraction 
from 35.5% ± 2.3% to 55.1% ± 8.2% (p<0.01) together with 
an improvement in the regional wall contractility (wall mo-
tion index from 3.02 ± 0.17 to 1.36 ± 0.14 (p<0.0001). PET 
(positron emission tomography) analysis also detected an 
increase in viabilty and perfusion levels. Importantly, other 
studies, tested a wide range of cell doses, from 4 x 105 to 5 x 
107 [82] or from 1-300 x 106 cell-dose [81] and although a 
few cases of arrhythmia were reported, overall, an improve-
ment in the cardiac function together with an increase in the 
viability and perfusion was determined. The study published 
by Siminiak et al including 10 patients reported an increase 
from 35.2% to 42.0% in LVEF 4 months after transplant 
which was maintained during the first year of follow-up. Dib 
et al (30 patients) showed an increase in the ejection fraction 
of 7% (from 28% to 35%; p<0.02) during the first year and 
8% after the second year (p<0.01) together with an im-
provement in tissue viability. Tachycardia episodes were 
detected in 3 of the patients. Interestingly, cells were deliv-
ered percutaneously, so the feasibility and safety of this route 
of transplantation were confirmed [86]. A second study was 
also performed by the group led by Serruys [79] proving also 
the safety of the method and documenting an increase in the 
global ejection fraction. Although all these data are quite 
suggestive, the small number of patients included in these 
studies as well as the lack of placebo groups make it impos-
sible to draw any definitive conclusion regarding the benefi-
cial effect of this approach. Very importantly, a randomized, 
double-blind, placebo-controlled dose-ranging trial 
(MAGIC) has recently been finished including 92 patients 
from different hospitals [87]. The study was performed in 
patients with a LVEF between 15 and 35%, a history of 
acute MI with residual akinesia and clinical indication for 
CABG (coronary artery bypass graft). Importantly, no sig-
nificant differences in survival and first ventricular arrhyth-
mia were detected among the three groups at 1 and 6 months. 
Furthermore, two doses of cells (400 x10
6
 and 800 x 10
6
) 
were tested. It was demonstrated that administration of the 
high cell dose significantly reduced the end-systolic and end-
diastolic volumes which translated into an increase of 3% in 
the LVEF compared with the placebo group (p=0.04). De-
spite some limitations in this trial like the low number of 
patients, the lack of long term follow-up and the functional 
quantification by echocardiography rather than magnetic 
resonance imaging (MRI), this study has helped to clarify the 
safety of skeletal myoblast treatment and suggest the relative 
efficiency of the treatment, opening new perspectives for 
treatment of MI provided that phase III trials confirm the 
results. 
Bone Marrow Derived-Sc Clinical Trials 
Bone marrow has been the most common source of SC 
tested in human clinical trials (See Table 2). The first trials 
performed determined the safety and feasibility of SC trans-
 
 
 
 
 
 
 
 
 
 
 
Fig. (1).  therapeutic potential: Mechanisms. SC transplantation could induce repair of sick tissue (i) by differentiating itself into the re-
quired tissue cell type or (ii) by secretion of cytokines responsible to trigger several mechanisms involved in anti-apoptotic signaling, cell 
proliferation, angiogeneic processes or recruitment of resident stem cells able to reconstitute the damaged tissue. To better understand the 
key factors involved in such processes would greatly help to improve the beneficial effect of the transplanted cells. 
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plantation, showing also a functional improvement [88-93]. 
However, these trials included a limited number of patients, 
and this, along with the lack of randomization and double-
blinded performance, meant that the reliability of the results 
could not be tested. Moreover, the significant heterogeneity 
in the type of cell populations used (BM-Mononuclear cells 
(BM-MNC), sorted BM fractions, in vitro cultured cells 
(MSCs) or G-CSF mobilized cells), the delivery route (endo-
cardial catheter-based or epicardial surgical-based or percu-
taneous catheter-based intracoronary injec tion) and the tim-
ing of transplantation all limited the conclusions of these 
studies. 
The first randomized trial, the BOOST I trial (BOne mar-
row transfer to enhance ST-elevation infarct regeneration) 
was performed in 60 patients with acute MI. Thirty of the 
patients received 2.5±0.9 x 10
9
 unfractionated BM-MNCs by 
intracoronary delivery ~6 days after occlusion. Although a 
control group that did not receive cells was included, no 
bone marrow aspiration or sham infusion was performed in
Table 1. Most relevant SkM transplantation Clinical Trials in CMI 
Study (Year) Cell 
Type 
Number of 
Patients 
(Treated/co) 
Cell-Dose 
(%cd56+ Cells) 
(x 10
6
) 
Delivery 
Time/ 
Route 
Follow-up 
Time 
(Months) 
%Lvef Increase 
(Basal vs. Treated) 
(p in Treated Group) 
Lvef Imag-
ing Asses-
ment 
Other Func-
tional Out-
comes 
Non-Randomized Controlled Trials 
Menasche et al. 
(75) 2003 
Hagege et al. 
(76) 2006 
SkM 10/0 780-1060 
(86) 
3-228m/ 
TEp w/o 
CABG 
10.9 
52 
8 (*) (10.9m) 
4 (NS) (52m) 
Echo ?Regional 
wall motion 
(at 10.9m); 
?Global 
LVEF (at 
10.9m). 
Smits et al. 
(85) 2003 
SkM 5/0 90-310 
(25-85D+) 
24-132m/ 
TEc 
3, 6 5 (**) (3m); 9 (NS) 
(6m) 
LV angi-
ography, 
Echo, MRI 
?Regional 
wall motion; 
?Global 
LVEF. 
Ince et al. (84) 
2004 
SkM 6/6 60-360 NP 
TEc 
(EMM) 
12 8 (*) 
Co: -3 
Echo ?Global 
LVEF. 
Gavira et al. 
(80) 2006 
SkM 12/14 190±120 
(65.6) 
3-168m 
TEp + 
CABG 
3, 12 8 (**) (3m), 9 (**) 
(12m) 
Co: 3 (NS) (12m) 
Echo ?Regional 
wall motion; 
?Global 
LVEF; ?Tis-
sue Viability; 
?Perfusion. 
Siminiak et al. 
(82) 2004 
SkM 10/0 0.4-50 
(65.4D+) 
4-108m/ 
TEp w/o 
CABG 
4, 12 7 (*) (4m), 7 (*) 
(12m) 
Echo ?Regional 
wall motion; 
?Global 
LVEF. 
Chachques et 
al. (83) 2004 
SkM 20/0 300±20 
(78±5D+) 
NP/ 
TEp w/o 
CABG 
9, 19 24 (*) Echo, 
SPECT 
?Regional 
wall motion; 
?Global 
LVEF; ?Tis-
sue Viability. 
Dib et al. (81) 
2005 
 
SkM 
30/0 2.2-300 
(42-98) 
NP/ 
TEp w/o 
CABG or 
LVAD 
12, 24 7 (*) (12m), 8 (*) 
(24m) 
Echo, 
SPECT, 
MRI 
?Regional 
wall motion; 
?Global 
LVEF; ?Tis-
sue Viability; 
?ESV; ?EDV. 
Siminiak et al. 
(86) 2005 
SkM 9/0 17-106 
(65) 
5-96m/ 
TC 
2.5 3-8 in 6/9 patients 
(Not statistically ana-
lyzed) 
Echo Symptoms 
improved. 
Biagini et al. 
(79) 2006 
SkM 10/0 217±111 
(64±27D+) 
28-140m/ 
TEc 
1, 3, 6, 12 6 (**) (12m) Echo, TDI ?Regional 
wall motion; 
?ESV; ?EDV. 
Randomized Controlled Trials 
MAGIC/ 
Menasche et al. 
(87) 2008 
SkM 30HD /34 
33LD /34 
800 (HD) 400 
(LD) 
(89) 
NP 
TEp + 
CABG 
6 0.8 (NS) (HD) Echo ?Global 
LVEF; ?ESV 
(HD). 
Abbreviations: SkM: Skeletal Myoblasts; Co: Control group; D+: desmin positive; NP: Not Provided; TEp: Transepicardial; TEc: Transendocardial; TC: Transcoroary; NS: Not 
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Table 2. Most Relevant BM Transplantation Clinical Trials in AMI 
Study 
(Year) 
Cell 
Type 
Number Of 
Patients 
(Treated/co) 
Cell-Dose 
(%cd34+ 
Cells) 
(x 10
6
) 
Sham? Delivery 
Time/ 
Route 
Follow-
up Time 
(Months) 
%Lvef Increase 
(Basal vs. Treated) 
(p in Treated 
Group) 
Lvef Im-
aging 
Assesment 
Other Func-
tional Out-
comes 
Non-
Random-
ized 
Controlled 
Trials 
         
Strauer et 
al. (93) 
2002 
BMC 20 (10/10) 9-28 (0.39) No 5-9d+/IC 3 4 vs 5; (NS) LV angi-
ography 
?ESV; 
?EDV; 
?Perfusion; 
?Regional 
wall motion; 
?Infarct 
Size. 
TOPCARE-
AMI / 
Assmus et 
al. (92) 
2002, 
Britten et al. 
(91) 2003, 
Schachinger 
et al. (88) 
2004. 
BMC/ 
CPC 
30 (19/11) 240(7.4) No 4d+/IC 4, 12 2.5 vs 8.5; (**) LV angi-
ography, 
Echo 
?ESV; 
?EDV; 
?Regional 
wall motion; 
?Infarct 
Size. 
Fernandez-
Aviles et al. 
(89) 2004 
BMC 33 (20/13) 37-119 No 8-19d+/IC 6 5.8; (**) Cardiac 
MRI  
?ESV; 
?EDV; 
?Thickness 
of infarct 
wall. 
Bartunek et 
al. (98) 
2005 
CD133
+ 
35 (19/16) NP (12.6) No 10.2-
13d+/IC 
4 4.3 vs 7.1; (*) SPECT, 
Echo 
?EDV; 
?Perfusion. 
Random-
ized  
Controlled 
Trials 
         
BOOST I / 
Wollert et 
al. (96) 
2004 
Schaefer 
(95) 2006 
BMC 60 (30/30) 2460 (9.5) No 6d+/IC 6, 18 0.7 vs 6.7; (**) (6m) 
3.1 vs 5.9; (NS) 
(18m) 
MRI  ?Infarct 
Size. 
Chen et al. 
(97) 2004 
MSC 69 (34/35) 4800-6000 Yes 18d+/IC 6 6 vs 8; (*) LV angi-
ography 
?ESV; 
?Perfusion;  
?Regional 
wall motion. 
Jannsens et 
al. (99) 
2006 
 
BMC 
66 304 (2.8) Yes 24h+/IC 4 2.2 vs 3.3 ; (NS) MRI ?Perfusion; 
?Infarct 
Size; 
?Tissue 
Viability. 
ASTAMI/ 
Lunde et al. 
(102) 2006, 
Lunde et al. 
(103) 2007 
BMC 97 (47/50) 68 (0.7) No 4-8d+/IC 6 6.7 vs 8; (NS) SPECT, 
MRI, Echo 
?ESV; 
?EDV; ?In-
farct Size; 
?Perfusion. 
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Table 2. Contd…. 
Study 
(Year) 
Cell 
Type 
Number Of 
Patients 
(Treated/co) 
Cell-Dose 
(%cd34+ 
Cells) 
(x 10
6
) 
Sham? Delivery 
Time/ 
Route 
Follow-
up Time 
(Months) 
%Lvef Increase 
(Basal vs. Treated) 
(p in Treated 
Group) 
Lvef Im-
aging 
Assesment 
Other Func-
tional Out-
comes 
REPAIR-
AMI/ 
Schachinger 
et al. (101) 
2006 
Erbs et al. 
(100) 2007 
BMC 204 
(101/103) 
236 (3.6) Yes 3-6d+/IC 4, 12 3 vs 5.5; (*) LV angi-
ography, 
MRI 
?ESV; 
?EDV; ?In-
farct Size. 
Meluzin et 
al. (105) 
2006 
Meluzin et 
al (104) 
2007 
BMC 66 
(22/22+22) 
100 (HD)  
10 (LD) 
No 6-10d+/IC 3, 6, 12 3 vs 6; (NS) (3m) 
0 vs 7; (*) (6m) 
(HD) 
0 vs 7; (**) (12m) 
(HD) 
SPECT, 
Echo 
?ESV; 
?EDV; 
?Perfusion. 
Abbreviations: BMC: Bone Marrow Cells. CPC: Blood derived-Circulating Progenitor Cells. Co: Control group. NP: Not Provided. HD: High cell Dose. IC: Intracoronary. NS: Not 
Significant. *: P<0.05. **: P<0.01. LV: Left Ventricular. Echo: Echocardiography. MRI: Magnetic Resonance Imaging. SPECT: Single Photon Emission Tomography. ESV: End 
Systolic Volume. EDV: End Diastolic Volume. 
the control group. After 6 months, an improvement in the 
ejection fraction (50.0% to 56.7% in treated vs. 51.3% to 
52.0% in controls) with no significant changes in the LV-
end-diastolic volumes or reduction of the infarct size, was 
demonstrated; Follow up of these patients showed that such 
improvement was transitory and by 18 months there was no 
statistical differences in the global LV ejection fraction be-
tween the control and the treated groups (3.1 percentage 
points in the control group vs. 5.9 in the treated group) [94-
96]. 
Close in time, another similar study performed with 
MSCs in 69 patients showed an improvement in the global 
LVEF (from 48±10 to 54±5 in the control group and from 
49±9 to 67±3 in the treated group; p=0.01), together with a 
reduction of the end-systolic and diastolic volumes and an 
improved contractility index, wall motion and velocity and 
increased tissue viability. Unfortunately, the functional stud-
ies were performed at 6 months and no long-term follow-up 
was performed [97]. In another clinical trial, CD133+ se-
lected BM-MNC were transferred to a series of 14 patients. 
Global LVEF, regional wall motion and tissue perfusion 
increased in the treated group after 4 months. However, sec-
ondary effects like restenosis or de novo lesions developed in 
6 of the 14 patients, provoking some concerns among the 
scientific community [98]. Importantly, in 2006, the group of 
Janssen et al. published the results of the first randomized, 
double-blinded, placebo-controlled trial [99]. In this study, 
intracoronary transplantation of BM-MNC was performed in 
33 patients with AMI, 24h after reperfusion (34 were in-
cluded as placebo). A reduction of the infarct size and a bet-
ter recovery of the regional systolic function were detected 
after 4 months, but no significant functional improvement or 
a significant improvement of myocardial perfusion and me-
tabolism indexes were detected. During the same year, the 
results of another two studies performed with a larger num-
ber of patients were also published. Contradictory results 
were obtained; whereas in the REPAIR-AMI trial (Reinfu-
sion of Enriched Progenitor Cells and Infarct Remodeling in 
Acute Myocardial Infarction), an improvement of the ejec-
tion fraction together with a reduction of the infarct size and 
a restoration of the microvascular function of the infarct-
related artery [100] 4 months after transplantation were seen 
[101], no differences were found in the ASTAMI trial 
(Autologous Stem Cell Transplantation in Acute Myocardial 
Infarction) [102] despite an improvement in exercise time 
and heart rate responses to exercise [103]. In both studies, 
the method of cell delivery (intracoronary) and the SC 
source used (BM-MNC) were similar. It is possible, how-
ever, that the timing of cell-delivery, the method of cell iso-
lation and/or the degree of severity on the patients condition 
could vary between these trials, explaining the contradictory 
results. Also, a slightly smaller number of cells (2-4 times 
fewer) was injected in the ASTAMI trial. Along similar 
lines, the last two studies published by Meluzin et al. 
[104,105] showed that the benefit of BM-MNC transplanta-
tion in acute MI can be cell-dose dependent. Three months 
after transplantation, a significant functional improvement 
was detected only in the group transplanted with the higher 
cell-dose (10
8
 cells vs. the lower cell-dose 10
7
 cells) with a 
5% vs. a 3% LVEF increase (p<0.05 vs. control group).  
A very interesting meta-analysis [106] of 10 controlled 
clinical trials performed with BM-MNC in patients with re-
cent acute MI (?14 days) has recently been published. The 
statistical results suggest that intracoronary cell therapy fol-
lowing percutaneous coronary intervention for acute MI can 
provide statistically and clinically relevant benefits for car-
diac function and remodeling. Moreover, it has also sug-
gested a dose-response association with such benefits.  
Finally, various other trials have been performed with 
mobilized cells after G-CSF treatment. The first clinical trial 
performed (Front-Integrated Revascularization and Stem cell 
Liberation In Evolving Acute Myocardial Infarction: 
FIRSTLINE-AMI) [107] [108] suggested an improvement of 
cardiac function, but a placebo-controlled clinical trial (RE-
generate VItal Myocardium by Vigorous Activation of bone 
marrow stem cells: REVIVAL II and STEM cells in Myo-
cardial Infarction: STEMMI) did not confirm such a benefit 
[109-111]. It could be argued that the late application of the 
G-CSF in the REVIVAL II study (5 days after reperfusion 
vs. 90 min) could be the cause of the different results in these 
studies. There is growing evidence that G-CSF could have a 
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more cardioprotective than cell-mediated effect [112], and 
therefore, the time of injection could be a critical factor for 
its positive effect. However, in the last randomized, double-
blind, placebo-controlled trial performed, the STEMMI trial, 
G-SCF was applied also at an earlier time-point (12h after 
reperfusion), with a similar pattern to the FIRSTLINE-AMI 
trial, although a functional benefit could not be detected. 
LVEF improved similarly in the control and treated groups 
measured both by MRI (8.5 vs. 8.0; p=0.9) and echocardi-
ography (5.7 vs. 3.7; p=0.7). Importantly, no clinical adverse 
effects were detected.  
In conclusion, performing multicenter randomized trials 
with long-term follow-up is mandatory in order to demon-
strate the efficacy of BM-MNC transplantation and to estab-
lish, for the greatest efficacy, the ideal cell type, cell-dose 
and surgical procedure (delivery route, transplantation time-
point, etc.).  
FUTURE STUDIES 
The scientific community and the media have hailed 
Stem Cell therapy as a therapeutic alternative for conven-
tional medicine based on pharmacologic treatment. The idea 
of replacing damaged tissues or dysfunctional cells -
sometimes due to genetic diseases- opened a new perspective 
on traditional medicine. However, although our basic knowl-
edge about these recently discovered cells is growing, there 
are many questions and technical limitations that need to be 
answered or solved in order to better apply these cells as an 
effective treatment. Both basic research and clinical trials 
suggest that SC transplantation has a positive effect in cer-
tain patients with myocardial infarction. However, it is still 
very important to investigate how to augment the stability of 
the cells once transplanted and also to understand the mo-
lecular mechanisms involved in such benefits. Due to the 
low engraftment and permanence of the transplanted cells in 
the heart, and the fact that they still resulted in functional 
improvement, it has been proposed that the factors and cyto-
kines released by the transplanted cells could trigger several 
mechanisms, such as angiogenesis, proliferation and protec-
tion, which could contribute to tissue regeneration. Although 
other mechanisms cannot be discarded, a better understand-
ing of the paracrine effect, identifying the key molecules and 
pathways responsible for such improvement, would enor-
mously help to direct the therapy in a more specific and effi-
cient way. Also, the differentiation pathways and molecular 
mechanisms at the protein, transcriptional and epigenetic 
levels are being studied intensely, in order to find ways to 
manipulate the differentiation of these cells towards the re-
quired cell type. This last issue is an important subject if we 
take into account the fact that even if the cells present multi- 
or pluri-potent capabilities, once they are transplanted in the 
sick tissue it is probable that they will not receive the proper 
signaling for it. One possible alternative to this limitation 
could be to transplant in vitro pre-differentiated cells. 
In summary, we could conclude from all the results re-
viewed until now that stem cell application in cardiovascular 
disease presents great potential and that we can be optimistic 
about its therapeutic potential. None the less, many studies 
need to be performed in order to understand their origin and 
behavior and to be able to apply them in routine clinical 
practice. 
ACKNOWLEDGEMENT 
Supported in part by grants from the Ministerio de Sani-
dad (PI042125, PI050168, PI070474), RETIC RD06/0014 
and the “UTE project CIMA” 
ABBREVIATIONS LIST 
ADSCs = pose Derived Stem Cells 
ASTAMI = Autologous Stem Cell Transplantation in 
cute Myocardial Infarction 
BM = Bone Marrow 
BM-MNC = Bone Marrow Mononuclear Cells 
BMP4 = Bone Morphogenetic protein 4 
BOOST = Bone Marrow transfer to enhance ST-
elevation infarct regeneration 
CABG = Coronary Artery Bypass Graft 
CMs = Cardiomyocytes 
CPCs = Cardiac Progenitor Cells 
3D = Three Dimensions 
EPCs = Endothelial Progenitor Cells 
FIRST- = Front-Integrated revascularization and 
INE-AMI  tem ell Liberation In Evolving Acute Myo 
  cardial nfarction 
G-CSF = Granulocyte-Colony Stimulating Factor 
GFP = Green Fluorescent Protein 
HSC = Hematopoietic Stem Cells 
LVEF = Left Ventricular Ejection Fraction 
MAGIC = Myoblast Autologous Grafting in Ischemic 
Cardiomyopathy 
MAPCs = Multipotent Adult Progenitor Cells 
MCP-1 = Monocyte Chemoattractant Protein-1 
MI = Myocardial Infarction 
MIAMI = Marrow-Isolated Adult Multilineage In-
ducible cells 
MRI = Magnetic Resonance Imaging 
MSC = Mesenchymal Stem Cells 
Oct4 = Octamer-4 
TNF-? = Tumor Necrosis Factor - ? 
PDGF-BB = Platelet-derived Growth Factor-BB 
PET = Positron Emission Tomography 
REPAIR- = Reinfusion of Enriched Progenitor Cells 
AMI  and Infarct Remodeling in Acute Myocar- 
  dial Infarction 
REVIVAL = Regenerate Vital Myocardium by Vigor-
ous Activation of bone marrow stem cells 
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Sca1 = Stem Cell Antigen-1 
Sk = Skeletal muscle 
SPOC = Skeletal Precursors Of Cardiomyocytes 
SSEA = Stage Specific Embryonic Antigen 
STEMMI = STEM cells in Myocardial Infarction 
SVF = Stromal Vascular Fraction 
TGF-?1 = Transforming Growth Factor -?1 
VEGF = Vascular Endothelial Growth Factor 
VSEL = Very Small Embryonic Like cells 
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